Free Trial

Voyager Therapeutics (VYGR) Competitors

Voyager Therapeutics logo
$5.11 +0.16 (+3.13%)
As of 01:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VYGR vs. UPB, RLAY, SPRY, SEPN, SANA, BCAX, COLL, PHAR, XNCR, and CRON

Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Upstream Bio (UPB), Relay Therapeutics (RLAY), ARS Pharmaceuticals (SPRY), Septerna (SEPN), Sana Biotechnology (SANA), Bicara Therapeutics (BCAX), Collegium Pharmaceutical (COLL), Pharming Group (PHAR), Xencor (XNCR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

Voyager Therapeutics vs. Its Competitors

Voyager Therapeutics (NASDAQ:VYGR) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Upstream Bio had 7 more articles in the media than Voyager Therapeutics. MarketBeat recorded 7 mentions for Upstream Bio and 0 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.51 beat Upstream Bio's score of 0.49 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Voyager Therapeutics Positive
Upstream Bio Neutral

48.0% of Voyager Therapeutics shares are held by institutional investors. 4.5% of Voyager Therapeutics shares are held by insiders. Comparatively, 13.6% of Upstream Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Voyager Therapeutics presently has a consensus price target of $12.96, suggesting a potential upside of 153.77%. Upstream Bio has a consensus price target of $53.33, suggesting a potential upside of 139.86%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Upstream Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Upstream Bio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Upstream Bio has lower revenue, but higher earnings than Voyager Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$80M3.54-$65M-$1.85-2.76
Upstream Bio$2.37M505.78-$62.81MN/AN/A

Voyager Therapeutics has a net margin of -253.49% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat Voyager Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics-253.49% -37.65% -28.89%
Upstream Bio -3,836.58%-35.90%-26.26%

Summary

Voyager Therapeutics beats Upstream Bio on 7 of the 13 factors compared between the two stocks.

Get Voyager Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYGR vs. The Competition

MetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$281.51M$3.47B$6.17B$10.68B
Dividend YieldN/A2.27%5.72%4.83%
P/E Ratio-2.7423.4029.4727.34
Price / Sales3.54479.21587.77132.79
Price / CashN/A45.2825.8230.35
Price / Book0.9310.5212.446.68
Net Income-$65M-$52.71M$3.32B$276.46M
7 Day Performance4.40%4.72%2.15%0.77%
1 Month Performance19.56%15.59%8.41%3.73%
1 Year Performance-36.74%13.83%61.67%36.59%

Voyager Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYGR
Voyager Therapeutics
4.3711 of 5 stars
$5.11
+3.1%
$12.96
+153.8%
-38.7%$281.51M$80M-2.74100
UPB
Upstream Bio
1.9619 of 5 stars
$20.08
+2.3%
$56.50
+181.4%
-19.0%$1.08B$2.37M0.0038
RLAY
Relay Therapeutics
2.1716 of 5 stars
$6.27
-3.5%
$16.50
+163.2%
-3.6%$1.08B$8.36M-3.22330Positive News
SPRY
ARS Pharmaceuticals
2.9749 of 5 stars
$10.93
-3.4%
$33.80
+209.2%
-37.1%$1.08B$89.15M-22.3190
SEPN
Septerna
1.3607 of 5 stars
$24.09
+4.4%
$26.75
+11.0%
N/A$1.07B$726K-2.39N/A
SANA
Sana Biotechnology
2.8154 of 5 stars
$4.34
+0.5%
$7.50
+72.8%
+18.9%$1.03BN/A-4.09380Gap Up
BCAX
Bicara Therapeutics
2.43 of 5 stars
$18.51
+4.1%
$31.86
+72.1%
-16.9%$1.01BN/A-5.8432Gap Up
COLL
Collegium Pharmaceutical
3.9435 of 5 stars
$32.04
flat
$42.33
+32.1%
-11.7%$1.01B$707.01M30.81210Analyst Downgrade
PHAR
Pharming Group
2.8055 of 5 stars
$14.61
+2.4%
$30.00
+105.3%
+52.8%$1.00B$297.20M-112.38280Positive News
Upcoming Earnings
Short Interest ↓
Gap Down
High Trading Volume
XNCR
Xencor
3.7379 of 5 stars
$13.96
+7.1%
$24.22
+73.5%
-32.2%$995.67M$146.93M-5.82280
CRON
Cronos Group
1.0266 of 5 stars
$2.55
+1.6%
N/A+14.2%$976.38M$130.28M51.00450Positive News

Related Companies and Tools


This page (NASDAQ:VYGR) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners